Metformin × glycemic control

SynthesisAtencion primaria2005

[Metformin for type-2 diabetes mellitus. Systematic review and meta-analysis].

A Sáenz Calvo et al.PubMed ↗Full text ↗Publisher ↗

What the trial testedas reported · 2005

Not counted

Probably lowered glycemic control

−1.21percentage points−1.48 to −0.94

As reported

difference −1.21 %, 95% CI −1.48 to −0.94

Not counted

Probably lowered glycemic control

−0.24−0.40 to −0.09

As reported

difference −0.24, 95% CI −0.40 to −0.09

Not counted

Probably lowered glycemic control

−0.11−0.18 to −0.04

As reported

difference −0.11, 95% CI −0.18 to −0.04

What moved togetherboth groups pooled, not the treatment’s effect

Correlation, not cause

Went with lower glycemic control

−22%−35% to −6%

Bigger than 2 in 10 for glycemic control

As reported

RR 0.78, 95% CI 0.65–0.94

Correlation, not cause

Went with lower glycemic control

−26%−40% to −10%

Bigger than 2 in 10 for glycemic control

As reported

RR 0.74, 95% CI 0.60–0.90

Five numbers in the abstract

the abstract, start to end

with diabetes (relative risk [RR]=0.78; 95% confidence interval [CI], 0.65-0.94) and than diet (RR=0.74; 95% CI, 0.60-0.90).

hemoglobin A1 (weighted mean difference, -1.21%; 95% CI, -1.48 to -0.94), low density lipoprotein cholesterol (weighted mean difference, -0.24; 95% CI, -0.40 to -0.09), and weight (standardized mean difference, -0.11; 95% CI, -0.18 to -0.04).

← favours treatmentfavours comparator →
could be chance
Glycemic control
RR 0.780.65–0.94
Glycemic control
RR 0.740.60–0.90
Glycemic control
−1.21−1.48 to −0.94
Glycemic control
−0.24−0.40 to −0.09
Glycemic control
−0.11−0.18 to −0.04
MetforminGlycemic control
1 / 3

5 papers cite it

2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
this papercites it
Full record →Abstract, authors, funding and every citing paper · PMID 16153370